MOUNTAIN VY MD INC - MVMDF STOCK NEWS

Mountain Valley MD Holdings Inc. (MVMD) announced the redemption of all issued and outstanding Class B Non-Voting Shares, following the disposition of Class B Investments for approximately $1,798,000. This decision affects only the Class B shareholders and will be executed on December 20, 2022, with the redemption price based on the proceeds from the sale. Notably, common shareholders will not be impacted by this transaction.

Mountain Valley MD Holdings Inc. (MVMD) has shifted its focus from R&D to commercialization, targeting three primary business areas: nutraceuticals, agricultural plant signaling technology, and husbandry animal health. The company aims to generate revenue streams in 2023 with a licensing agreement for its proprietary technologies, including Quicksome™ and Quicksol™. MVMD's partnership with Agrarius Corp. aims to enhance crop yields and reduce fertilizer usage. The company's advancements include a positive outlook on products launched by Circadian Wellness Corp. and anticipated revenue from its agricultural product trials.

Mountain Valley MD Holdings Inc. (MVMD) has announced the launch of commercial sales of Agrarius, a certified organic product aimed at enhancing agricultural crop yields, reducing fertilizer use, and improving resilience to environmental stresses. Agrarius activates plants' defense mechanisms, leading to yield increases of 10% to 50% while decreasing fertilizer usage by over 30%. MVMD is an authorized reseller of Agrarius, which received organic certification. CEO Dennis Hancock emphasized this launch aligns with MVMD’s goal of becoming cash-flow positive in 2023 amidst current global fertilizer shortages.

Mountain Valley MD Holdings Inc. (MVMDF) has successfully completed a pre-clinical pharmacokinetic study (IM032) of its new drug Soluvec™ in male beagle dogs. The study compared intramuscular and subcutaneous dosing of Soluvec™ with oral ivermectin. Results showed that Soluvec™ produced significantly higher plasma concentrations and systemic exposure than ivermectin. The company plans to submit a regulatory package for a pre-IND meeting with the FDA under the 505(b)(2) pathway for expedited drug approval.

Mountain Valley MD Holdings Inc. (CSE: MVMD, OTCQX: MVMDF) provided a business update highlighting its advanced technologies designed to enhance drug efficacy, administration, and safety. Key technologies include Quicksome™ for cold chain management of vaccines and Quicksol™ for solubilizing anti-parasitic drugs. The company is also expanding its focus into needleless insulin delivery and tackling tuberculosis with its Selactosol™ product. Ongoing collaborations aim to optimize applications across various health sectors, with pre-clinical studies expected to commence later in 2022.

Mountain Valley MD Holdings Inc. (MVMD) appointed Dr. Elizabeth Norton to an advisory role to enhance its Quicksome™ vaccine and cold chain projects. Dr. Norton, an experienced immunologist, has a solid background in vaccines and public health and currently serves as an Associate Professor at Tulane University. She takes over from Dr. John D. Clements, who is retiring but will continue to assist on an ad-hoc basis. MVMD aims to improve global vaccine access and effectiveness through its innovative Quicksome™ technology.

Mountain Valley MD Holdings announced the adoption of a restricted share unit plan (RSU Plan) and granted 875,000 RSUs and 2,525,000 stock options. The RSUs vest based on performance milestones to be achieved by December 31, 2022. The options, exercisable at $0.22 per share, have a vesting schedule over one year. MVMD aims to align employee incentives with long-term shareholder value while preserving cash expenditures, promoting its patented Quicksome™ and Quicksol™ technologies for effective drug and vaccine delivery.

Mountain Valley MD Holdings Inc. (MVMD) announced a Product Development and Commercial Licensing Agreement with Red White & Bloom Brands Inc. (RWB). This collaboration will leverage MVMD's Quicksome™ technology to create innovative cannabis products. RWB gains an exclusive five-year license to manufacture and distribute these products in Florida, Michigan, and California, alongside payment of product fees and sales royalties. The initial product will be a THC-based sleep formulation aimed at the medical sleep market. MVMD is also finalizing a patent to protect its cannabinoid solubilization techniques.

Mountain Valley MD Holdings Inc. (MVMD) provided a business update on September 29, 2021, detailing advancements in oncology research, husbandry animal trials, and the development of its ivermectin formulations.

Key initiatives include expanded oncology trials for triple-negative breast cancer and melanoma, successful husbandry trials in Bangladesh with Ivectosol™ 1%, and the introduction of Ivectol™ for generic ivermectin production. The company plans commercialization in 2022 pending approvals. Shareholders approved board re-elections and an independent auditor but rejected a share consolidation proposal.